A Phase 3 interventional study of ST10-021 and Placebo Comparator in Iron Deficiency Anaemia, Inflammatory Bowel Disease and Ulcerative Colitis, sponsored by Shield Therapeutics. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-30.
Sponsored by Shield Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing ferric maltol in Anemia, Iron-Deficiency — none open to participants now, none under way, none of them phase 3. ferric maltol · Anemia, Iron-Deficiency.
Among the 12 studies testing ferric maltol in Anemia, Iron-Deficiency, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 7 in phase 3, and was the 1st registered.
601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.
Browse Anemia, Iron-Deficiency studies →None of the 12 studies testing ferric maltol in Anemia, Iron-Deficiency is open now. The open studies under Anemia, Iron-Deficiency, anywhere →
ferric maltol: first FDA approval 2019 (ACCRUFER), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 128 is above the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 78 across the 12 interventional studies. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 4 most frequent:
Shield Therapeutics is the lead sponsor of 8 studies on the registry; none are open to participants now.
Shield Therapeutics has 8 studies filed under Anemia, Iron-Deficiency — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing ferric maltol in Anemia, Iron-Deficiency, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether ST10-021, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in subjects with non-active ulcerative colitis (UC).
As no curative treatment is currently available for ulcerative colitis (UC), treatment options are restricted to controlling symptoms, maintaining remission and preventing relapse. As such, treatment of iron deficiency anaemia (IDA), a key symptom of the disease, is integral to the medical management of UC. Iron deficiency anaemia in UC is a chronically debilitating disorder which has a significant impact on the quality of life of affected subjects. Characteristic symptoms of IDA include chronic fatigue, headache, and subtle impairment of cognitive function. Up to one third of subjects with UC suffer from recurrent anaemia, with hospitalization required in severe cases. First line standard therapy for mild to moderate IDA in UC is typically oral ferrous products (OFP), however this is often not successful. Many subjects are intolerant and suffer from continuously occurring side effects, occasional exacerbation of inflammatory lesions and failure to correct iron deficiency. Common adverse effects of OFP include nausea, epigastric discomfort and constipation, all of which are dose-related and appear especially evident in subjects with UC.
As compared to oral ferrous iron, oral ferric iron can be administered with improved tolerability and the total dose exposure of unabsorbed iron within the gastrointestinal tract is significantly reduced. In addition, the iron is retained in its chelated form if not absorbed and this may reduce the risk of irritation within the gastrointestinal tract. Clinical studies conducted to date provide preliminary evidence for the therapeutic potential of ST10-021 in patients with IDA in Inflammatory Bowel Disease, including UC.
The purpose of this study is to determine whether ST10-021 is safe and effective in the treatment of IDA in subjects with non-active UC. In an effort to target an underserved population, the study will include only those subjects who have failed OFP in the past, or where OFP cannot be used.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
Drug: ST10-021
Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
Drug: Placebo Comparator
30 mg capsules to be taken orally twice a day for 12 weeks
Also known as: Ferric Trimaltol, Ferric maltol, Feraccru
Matching sugar pill to be taken orally twice a day for 12 weeks
Change in Haemoglobin (Hb) Concentration From Baseline to Week 12 (Full Analysis Set, FAS)
Primary efficacy endpoint, defined as the change in Hb concentration from Baseline to Week 12. Baseline was defined as the pre-dose Hb concentration measured at the Randomisation Visit (Week 0). Missing Randomisation Hb values were replaced by Screening Hb values, if the randomisation was within the protocol-specified window. Hb concentration (g/dL) was analysed by a central laboratory from blood samples collected at every clinic visit: Screening, Randomisation (Week 0), Weeks 4, 8, 12, 14, 16, 20, 24, 36, 48, 64, Weeks 14 to 64 were open-label. The baseline, absolute concentration and change from baseline in Hb at all post-randomisation visits were listed and summarised by week using descriptive statistics. An analysis of covariance (ANCOVA) was used to analyse the primary endpoint; this included treatment, gender and disease as factors and baseline Hb as a covariate.
Time frame: Baseline to Week 12 - double-blind phase
Proportion of Subjects That Achieved ≥1 g/dL Change From Baseline in Hb Concentration at Week 12 (Full Analysis Set, FAS)
Logistic regression analysis of proportion of subjects that achieved ≥1 g/dL change from baseline in Hb concentration at Week 12 in the double-blind phase
Time frame: Subjects that achieved ≥1 g/dL change from baseline in Hb concentration at Week 12 - double-blind phase
Proportion of Subjects That Achieved ≥2 g/dL Change From Baseline in Hb Concentration at Week 12 (Full Analysis Set, FAS)
Logistic regression analysis of proportion of subjects that achieved ≥2 g/dL change from baseline in Hb concentration at Week 12 in the double-blind phase
Time frame: Baseline to Week 12 - double-blind phase
Proportion of Subjects That Achieved Hb Concentration Within Normal Range at Week 12 (Full Analysis Set, FAS)
Logistic regression analysis of proportion of subjects that achieved Hb concentration within normal range at Week 12 - end of double-blind phase
Time frame: Baseline to Week 12 - double-blind phase
Change in Hb Concentration From Baseline to Week 4 (Full Analysis Set, FAS)
ANCOVA analysis of the change in Hb concentration from Baseline to Week 4 of the double-blind phase - Full Analysis Set, multiple imputation
Time frame: Baseline to Week 4 - double-blind phase
Change in Hb Concentration From Baseline to Week 8 (Full Analysis Set, FAS)
ANCOVA analysis of Change in Hb concentration from Baseline to Week 8 of double-blind phase - FAS, multiple imputation
Time frame: Baseline to Week 8 - double-blind phase
Change in Haemoglobin Concentration From Baseline to Week 16 (Full Analysis Set, FAS)
Change in Haemoglobin Concentration from Baseline to Week 16 (FAS), after 12-week double-blind phase and first 4 weeks of open-label ST10 treatment.
Time frame: Baseline to Week 16 - open-label phase
Change in Haemoglobin Concentration From Baseline to Week 20 (Full Analysis Set, FAS)
Change in Haemoglobin Concentration from Baseline to Week 20 (FAS), after 12-week double-blind phase and then 8 weeks of open-label ST10 treatment
Time frame: Baseline to Week 20 - open-label phase
Change in Haemoglobin Concentration From Baseline to Week 24 (Full Analysis Set, FAS)
Change in Haemoglobin Concentration from Baseline to Week 24 (FAS), after 12-week double-blind phase and then 12 weeks of open-label ST10 treatment
Time frame: Baseline to Week 24 - open-label phase
Change in Haemoglobin Concentration From Baseline to Week 36 (Full Analysis Set, FAS)
Change in Haemoglobin Concentration from Baseline to Week 36 (FAS), after 12-week double-blind phase and then 24 weeks of open-label ST10 treatment
Time frame: Baseline to Week 36 - open-label phase
Change in Haemoglobin Concentration From Baseline to Week 48 (Full Analysis Set, FAS)
Change in Haemoglobin Concentration from Baseline to Week 48 (FAS), after 12-week double-blind phase and then 36 weeks of open-label ST10 treatment
Time frame: Baseline to Week 48 - open-label phase
Change in Haemoglobin Concentration From Baseline to Week 64 (Full Analysis Set, FAS)
Change in Haemoglobin Concentration from Baseline to Week 64 (FAS), after 12-week double-blind phase and then 52 weeks of open-label ST10 treatment
Time frame: Baseline to Week 64 - open-label phase
Change in Haemoglobin Concentration From Baseline to Week 64 EOS (Full Analysis Set, FAS)
Change in Haemoglobin Concentration from Baseline to Week 64 EOS (FAS) - Week 64 was re-categorised as Week 64 EOS for those subjects who withdrew from the study early and the 'Week 64' visit was outside the visit window of 64 weeks ± 2 days
Time frame: Baseline to Week 64 EOS - open-label phase
Proportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 16 (Full Analysis Set, FAS)
Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 16 (Full Analysis Set), after 12-week double-blind phase and first 4 weeks of open-label ST10 treatment
Time frame: Baseline to Week 16 - open-label phase
Proportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 36 (Full Analysis Set, FAS)
Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 36 (Full Analysis Set), after 12-week double-blind phase and 24 weeks of open-label ST10 treatment
Time frame: Baseline to Week 36 - open-label phase
Proportion of Subjects That Achieved Haemoglobin Concentration Within Normal Range at Week 64 (Full Analysis Set, FAS)
Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 64 (Full Analysis Set), after 12-week double-blind phase and 52 weeks of open-label ST10 treatment
Time frame: Baseline to Week 64 - open-label phase
Change in Haemoglobin Concentration From Baseline to Week 12 (Per Protocol Analysis Set, PPAS)
ANCOVA sensitivity analysis of the Primary efficacy endpoint analysis on the PPAS - Change in Haemoglobin Concentration from Baseline to Week 12
Time frame: Baseline to Week 12 - double-blind phase
Change in Haemoglobin Concentration From Baseline to Week 12 (Full Analysis Set [FAS] LOCF)
ANCOVA sensitivity analysis of the Primary efficacy endpoint analysis on the FAS LOCF - Change in Haemoglobin Concentration from Baseline to Week 12
Time frame: Baseline to Week 12 - double-blind phase
Change in Serum Ferritin Concentration From Baseline to Week 12 (Full Analysis Set, FAS)
Change in serum Ferritin concentration from Baseline to Week 12 (Full Analysis Set), after 12-week double-blind phase
Time frame: Baseline to Week 12 - double-blind phase
Change in Serum Ferritin Concentration From Baseline to Week 64 (Full Analysis Set, FAS)
Change in serum Ferritin concentration from Baseline to Week 64 (FAS), after 12-week double-blind phase and 52 weeks open-label ST10 treatment
Time frame: Baseline to Week 64 - open-label phase
Change in Serum TSAT% From Baseline to Week 12 (Full Analysis Set, FAS)
Change in serum TSAT% from Baseline to Week 12 (FAS), after 12-week double-blind phase
Time frame: Baseline to Week 12 - double-blind phase
Change in Serum TSAT% From Baseline to Week 64 (Full Analysis Set, FAS)
Change in serum TSAT% from Baseline to Week 64 (Full Analysis Set), after 12-week double-blind phase and 52 weeks open-label ST10 treatment
Time frame: Baseline to Week 64 - open-label phase
Irritable Bowel Disease Questionnaire (IBDQ) Score at Week 12 (Full Analysis Set, FAS)
Irritable Bowel Disease Questionnaire (IBDQ) score at Week 12 (FAS), end of double-blind phase. The IBDQ was developed as an activity index for determining the effect of Ulcerative Colitis symptoms on perceived quality of life. It is a 32-item questionnaire with four dimensions: bowel function, emotional status, systemic symptoms and social function. Total IBDQ score ranges from 32 to 224, with higher scores indicating better quality of life. The score of patients in remission usually is between 170 and 190.
Time frame: Week 12 - double-blind phase
Irritable Bowel Disease Questionnaire (IBDQ) Score at Week 64 (Full Analysis Set, FAS)
Irritable Bowel Disease Questionnaire (IBDQ) score at Week 64 (FAS), after 12-week double-blind phase and 52 weeks of open-label ST10 treatment. The IBDQ was developed as an activity index for determining the effect of Ulcerative Colitis symptoms on perceived quality of life. It is a 32-item questionnaire with four dimensions: bowel function, emotional status, systemic symptoms and social function. Total IBDQ score ranges from 32 to 224, with higher scores indicating better quality of life. The score of patients in remission usually is between 170 and 190.
Time frame: Week 64 - open-label phase
Change From Baseline in Simple Clinical Colitis Activity Index (SCCAI) Score at Week 12 (Full Analysis Set, FAS)
Change from baseline in Simple Clinical Colitis Activity Index (SCCAI) score at Week 12 (FAS), end of double-blind phase (in subjects with UC). The SCCAI is a diagnostic and research questionnaire used to assess the severity of symptoms in people who suffer from UC. The calculated score ranges from 0 to 19, where active disease is a score of 5 or higher. The score is determined by asking the person with UC questions regarding: * bowel frequency at day/night * urgency of defecation * blood in stool * general health * extracolonic manifestations
Time frame: Baseline to Week 12 - double-blind phase
Change From Baseline in Simple Clinical Colitis Activity Index (SCCAI) Score at Week 64 (Full Analysis Set)
Change from baseline in Simple Clinical Colitis Activity Index (SCCAI) score at Week 64 (FAS), after 12-week double-blind phase and 52 weeks open-label ST10 treatment (in participants with UC only). The SCCAI is a diagnostic and research questionnaire used to assess the severity of symptoms in people who suffer from UC. The calculated score ranges from 0 to 19, where active disease is a score of 5 or higher. The score is determined by asking the person with UC questions regarding: * bowel frequency at day/night * urgency of defecation * blood in stool * general health * extracolonic manifestations
Time frame: Baseline to Week 64 - open-label phase
Potential subjects were selected from the general population attending each centre in UK, DE, AT or HU for routine care of their IBD and anaemia. Individuals interested in participating were invited for the Screening visit in order to assess eligibility. Written informed consent was obtained prior to conducting any study specific assessments.
| Milestone | ST10 | Placebo | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|---|---|
| Started | 64 | 64 | 0 | 0 |
| Completed | 55 | 53 | 0 | 0 |
| Not completed | 9 | 11 | 0 | 0 |
| Withdrew: Adverse event | 6 | 4 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 5 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Milestone | ST10 | Placebo | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|---|---|
| Started | 0 | 0 | 50 | 47 |
| Completed | 0 | 0 | 37 | 36 |
| Not completed | 0 | 0 | 13 | 11 |
| Withdrew: Physician decision | 0 | 0 | 2 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 8 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 6 |
| Withdrew: Worsening of ibd | 0 | 0 | 1 | 0 |
Primary efficacy endpoint, defined as the change in Hb concentration from Baseline to Week 12. Baseline was defined as the pre-dose Hb concentration measured at the Randomisation Visit (Week 0). Missing Randomisation Hb values were replaced by Screening Hb values, if the randomisation was within the protocol-specified window. Hb concentration (g/dL) was analysed by a central laboratory from blood samples collected at every clinic visit: Screening, Randomisation (Week 0), Weeks 4, 8, 12, 14, 16, 20, 24, 36, 48, 64, Weeks 14 to 64 were open-label. The baseline, absolute concentration and change from baseline in Hb at all post-randomisation visits were listed and summarised by week using descriptive statistics. An analysis of covariance (ANCOVA) was used to analyse the primary endpoint; this included treatment, gender and disease as factors and baseline Hb as a covariate.
| g/dL | ST10 | Placebo |
|---|---|---|
| Change in Haemoglobin (Hb) Concentration From Baseline to Week 12 (Full Analysis Set, FAS) | 2.26 ± 1.184 | 0.01 ± 0.764 |
Logistic regression analysis of proportion of subjects that achieved ≥1 g/dL change from baseline in Hb concentration at Week 12 in the double-blind phase
| Participants | ST10 | Placebo |
|---|---|---|
| Yes | 50 | 7 |
| No | 14 | 57 |
Logistic regression analysis of proportion of subjects that achieved ≥2 g/dL change from baseline in Hb concentration at Week 12 in the double-blind phase
| Participants | ST10 | Placebo |
|---|---|---|
| Yes | 36 | 0 |
| No | 28 | 64 |
Logistic regression analysis of proportion of subjects that achieved Hb concentration within normal range at Week 12 - end of double-blind phase
| Participants | ST10 | Placebo |
|---|---|---|
| Yes | 42 | 8 |
| No | 22 | 56 |
ANCOVA analysis of the change in Hb concentration from Baseline to Week 4 of the double-blind phase - Full Analysis Set, multiple imputation
| g/dL | ST10 | Placebo |
|---|---|---|
| Change in Hb Concentration From Baseline to Week 4 (Full Analysis Set, FAS) | 1.08 ± 0.676 | 0 ± 0.67 |
ANCOVA analysis of Change in Hb concentration from Baseline to Week 8 of double-blind phase - FAS, multiple imputation
| g/dL | ST10 | Placebo |
|---|---|---|
| Change in Hb Concentration From Baseline to Week 8 (Full Analysis Set, FAS) | 1.79 ± 1.037 | 0.04 ± 0.722 |
Change in Haemoglobin Concentration from Baseline to Week 16 (FAS), after 12-week double-blind phase and first 4 weeks of open-label ST10 treatment.
| g/dL | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Change in Haemoglobin Concentration From Baseline to Week 16 (Full Analysis Set, FAS) | 2.34 ± 1.281 | 1.04 ± 1.023 |
Change in Haemoglobin Concentration from Baseline to Week 20 (FAS), after 12-week double-blind phase and then 8 weeks of open-label ST10 treatment
| g/dL | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Change in Haemoglobin Concentration From Baseline to Week 20 (Full Analysis Set, FAS) | 2.45 ± 1.213 | 1.46 ± 1.056 |
Change in Haemoglobin Concentration from Baseline to Week 24 (FAS), after 12-week double-blind phase and then 12 weeks of open-label ST10 treatment
| g/dL | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Change in Haemoglobin Concentration From Baseline to Week 24 (Full Analysis Set, FAS) | 2.68 ± 1.127 | 1.87 ± 1.195 |
Change in Haemoglobin Concentration from Baseline to Week 36 (FAS), after 12-week double-blind phase and then 24 weeks of open-label ST10 treatment
| g/dL | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Change in Haemoglobin Concentration From Baseline to Week 36 (Full Analysis Set, FAS) | 2.85 ± 1.227 | 2.17 ± 1.048 |
Change in Haemoglobin Concentration from Baseline to Week 48 (FAS), after 12-week double-blind phase and then 36 weeks of open-label ST10 treatment
| g/dL | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Change in Haemoglobin Concentration From Baseline to Week 48 (Full Analysis Set, FAS) | 3.09 ± 1.339 | 2.0 ± 1.191 |
Change in Haemoglobin Concentration from Baseline to Week 64 (FAS), after 12-week double-blind phase and then 52 weeks of open-label ST10 treatment
| g/dL | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Change in Haemoglobin Concentration From Baseline to Week 64 (Full Analysis Set, FAS) | 3.07 ± 1.457 | 2.19 ± 1.605 |
Change in Haemoglobin Concentration from Baseline to Week 64 EOS (FAS) - Week 64 was re-categorised as Week 64 EOS for those subjects who withdrew from the study early and the 'Week 64' visit was outside the visit window of 64 weeks ± 2 days
| g/dL | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Change in Haemoglobin Concentration From Baseline to Week 64 EOS (Full Analysis Set, FAS) | 1.32 ± 1.713 | 0.52 ± 1.417 |
Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 16 (Full Analysis Set), after 12-week double-blind phase and first 4 weeks of open-label ST10 treatment
| Participants | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Yes | 36 | 17 |
| No | 10 | 28 |
Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 36 (Full Analysis Set), after 12-week double-blind phase and 24 weeks of open-label ST10 treatment
| Participants | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Yes | 35 | 29 |
| No | 6 | 7 |
Proportion of subjects that achieved Haemoglobin Concentration within normal range at Week 64 (Full Analysis Set), after 12-week double-blind phase and 52 weeks of open-label ST10 treatment
| Participants | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Yes | 31 | 30 |
| No | 5 | 6 |
ANCOVA sensitivity analysis of the Primary efficacy endpoint analysis on the PPAS - Change in Haemoglobin Concentration from Baseline to Week 12
| g/dL | ST10 | Placebo |
|---|---|---|
| Change in Haemoglobin Concentration From Baseline to Week 12 (Per Protocol Analysis Set, PPAS) | 2.23 ± 0.13 | 0.05 ± 0.13 |
ANCOVA sensitivity analysis of the Primary efficacy endpoint analysis on the FAS LOCF - Change in Haemoglobin Concentration from Baseline to Week 12
| g/dL | ST10 | Placebo |
|---|---|---|
| Change in Haemoglobin Concentration From Baseline to Week 12 (Full Analysis Set [FAS] LOCF) | 2.11 ± 0.12 | -0.03 ± 0.12 |
Change in serum Ferritin concentration from Baseline to Week 12 (Full Analysis Set), after 12-week double-blind phase
| μg/dL | ST10 | Placebo |
|---|---|---|
| Change in Serum Ferritin Concentration From Baseline to Week 12 (Full Analysis Set, FAS) | 17.3 ± 28.3 | 1.2 ± 7.85 |
Change in serum Ferritin concentration from Baseline to Week 64 (FAS), after 12-week double-blind phase and 52 weeks open-label ST10 treatment
| μg/dL | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Change in Serum Ferritin Concentration From Baseline to Week 64 (Full Analysis Set, FAS) | 60.4 ± 93.35 | 36.6 ± 46.8 |
Change in serum TSAT% from Baseline to Week 12 (FAS), after 12-week double-blind phase
| % serum TSAT | ST10 | Placebo |
|---|---|---|
| Change in Serum TSAT% From Baseline to Week 12 (Full Analysis Set, FAS) | 18.0 ± 20.17 | -0.4 ± 7.82 |
Change in serum TSAT% from Baseline to Week 64 (Full Analysis Set), after 12-week double-blind phase and 52 weeks open-label ST10 treatment
| % serum TSAT | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Change in Serum TSAT% From Baseline to Week 64 (Full Analysis Set, FAS) | 18.8 ± 12.46 | 17.7 ± 16.2 |
Irritable Bowel Disease Questionnaire (IBDQ) score at Week 12 (FAS), end of double-blind phase. The IBDQ was developed as an activity index for determining the effect of Ulcerative Colitis symptoms on perceived quality of life. It is a 32-item questionnaire with four dimensions: bowel function, emotional status, systemic symptoms and social function. Total IBDQ score ranges from 32 to 224, with higher scores indicating better quality of life. The score of patients in remission usually is between 170 and 190.
| score on a scale | ST10 | Placebo |
|---|---|---|
| Irritable Bowel Disease Questionnaire (IBDQ) Score at Week 12 (Full Analysis Set, FAS) | 178.3 ± 32.36 | 176.3 ± 31.5 |
Irritable Bowel Disease Questionnaire (IBDQ) score at Week 64 (FAS), after 12-week double-blind phase and 52 weeks of open-label ST10 treatment. The IBDQ was developed as an activity index for determining the effect of Ulcerative Colitis symptoms on perceived quality of life. It is a 32-item questionnaire with four dimensions: bowel function, emotional status, systemic symptoms and social function. Total IBDQ score ranges from 32 to 224, with higher scores indicating better quality of life. The score of patients in remission usually is between 170 and 190.
| score on a scale | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Irritable Bowel Disease Questionnaire (IBDQ) Score at Week 64 (Full Analysis Set, FAS) | 180.7 ± 30.14 | 177.2 ± 36.97 |
Change from baseline in Simple Clinical Colitis Activity Index (SCCAI) score at Week 12 (FAS), end of double-blind phase (in subjects with UC). The SCCAI is a diagnostic and research questionnaire used to assess the severity of symptoms in people who suffer from UC. The calculated score ranges from 0 to 19, where active disease is a score of 5 or higher. The score is determined by asking the person with UC questions regarding: * bowel frequency at day/night * urgency of defecation * blood in stool * general health * extracolonic manifestations
| score on a scale | ST10 | Placebo |
|---|---|---|
| Change From Baseline in Simple Clinical Colitis Activity Index (SCCAI) Score at Week 12 (Full Analysis Set, FAS) | 0 (-2 to 5) | 0 (-1 to 5) |
Change from baseline in Simple Clinical Colitis Activity Index (SCCAI) score at Week 64 (FAS), after 12-week double-blind phase and 52 weeks open-label ST10 treatment (in participants with UC only). The SCCAI is a diagnostic and research questionnaire used to assess the severity of symptoms in people who suffer from UC. The calculated score ranges from 0 to 19, where active disease is a score of 5 or higher. The score is determined by asking the person with UC questions regarding: * bowel frequency at day/night * urgency of defecation * blood in stool * general health * extracolonic manifestations
| score on a scale | ST10 - Open-label Continuation From Active Arm in Double-blind | Placebo Switch to Open-label Extension ST10 Treatment |
|---|---|---|
| Change From Baseline in Simple Clinical Colitis Activity Index (SCCAI) Score at Week 64 (Full Analysis Set) | 0 (-3 to 2) | 0 (-2 to 5) |
Collected over Adverse events (AEs) were solicited after informed consent and until 4 weeks after the last dose of study drug (at study completion or early termination).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ST10 - Safety Set, Double-blind Phase | 0/64 (0%) | 1/64 (1.6%) | 39/64 (60.9%) |
| Placebo - Safety Set, Double-blind Phase | 0/64 (0%) | 2/64 (3.1%) | 46/64 (71.9%) |
| ST10 Continuation - Safety Set, Open-label Phase | 0/50 (0%) | 8/50 (16%) | 40/50 (80%) |
| Placebo Switch to ST10 Treatment-Safety Set, Open-label Phase | 0/47 (0%) | 2/47 (4.3%) | 35/47 (74.5%) |
| Event | ST10 - Safety Set, Double-blind Phase | Placebo - Safety Set, Double-blind Phase | ST10 Continuation - Safety Set, Open-label Phase | Placebo Switch to ST10 Treatment-Safety Set, Open-label Phase |
|---|---|---|---|---|
| Abdominal PainGastrointestinal disorders | 1/64 | 0/64 | 2/50 | 0/47 |
| Angina pectorisCardiac disorders | 0/64 | 0/64 | 0/50 | 1/47 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/64 | 0/64 | 0/50 | 1/47 |
| PneumoniaInfections and infestations | 0/64 | 0/64 | 0/50 | 1/47 |
| Colitis ulcerativeGastrointestinal disorders | 0/64 | 0/64 | 1/50 | 0/47 |
| Cholesteatoma removalSurgical and medical procedures | 0/64 | 0/64 | 1/50 | 0/47 |
| HerniaGeneral disorders | 0/64 | 0/64 | 1/50 | 0/47 |
| Rectal haemorrhageGastrointestinal disorders | 0/64 | 0/64 | 1/50 | 0/47 |
| Herpes zosterInfections and infestations | 0/64 | 0/64 | 1/50 | 0/47 |
| PeritonitisInfections and infestations | 0/64 | 0/64 | 1/50 | 0/47 |
| Event | ST10 - Safety Set, Double-blind Phase | Placebo - Safety Set, Double-blind Phase | ST10 Continuation - Safety Set, Open-label Phase | Placebo Switch to ST10 Treatment-Safety Set, Open-label Phase |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/64 | 8/64 | 12/50 | 8/47 |
| Abdominal painGastrointestinal disorders | 7/64 | 5/64 | 2/50 | 7/47 |
| Colitis ulcerativeGastrointestinal disorders | 0/64 | 0/64 | 4/50 | 6/47 |
| DiarrhoeaGastrointestinal disorders | 5/64 | 4/64 | 4/50 | 6/47 |
| Crohn's diseaseGastrointestinal disorders | 0/64 | 4/64 | 2/50 | 5/47 |
| Abdominal pain upperGastrointestinal disorders | 1/64 | 3/64 | 1/50 | 4/47 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/64 | 0/64 | 4/50 | 3/47 |
| ConstipationGastrointestinal disorders | 5/64 | 1/64 | 2/50 | 1/47 |
| FlatulenceGastrointestinal disorders | 4/64 | 0/64 | 3/50 | 3/47 |
| NauseaGastrointestinal disorders | 0/64 | 1/64 | 2/50 | 3/47 |
Potential subjects were screened for eligibility to participate based on their demographics, medical/surgical history, physical examination, concomitant medications, vital signs, clinical laboratory tests (including pregnancy test for females of child-bearing potential) and current IBD disease status (based on SCCAI clinical score). FAS - Safety
| Age, Categorical(Participants) | ST10 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 62 | 63 | 125 |
| >=65 years | 2 | 1 | 3 |
| Age, Continuous(years) | ST10 | Placebo | Total |
|---|---|---|---|
| Mean | 40.1 ± 13.52 | 38.5 ± 12.3 | 39.2 ± 12.9 |
| Sex: Female, Male(Participants) | ST10 | Placebo | Total |
|---|---|---|---|
| Female | 40 | 43 | 83 |
| Male | 24 | 21 | 45 |
| Region of Enrollment(participants) | ST10 | Placebo | Total |
|---|---|---|---|
| United Kingdom | 15 | 10 | 25 |
| Hungary | 11 | 15 | 26 |
| Germany | 35 | 32 | 67 |
| Austria | 4 | 6 | 10 |
| Duration of ulcerative colitis (years)(years) | ST10 | Placebo | Total |
|---|---|---|---|
| Mean | 9.0 ± 8.28 | 10.99 ± 11.43 | 9.99 ± 9.8 |
| Time since last IBD flare-up (months)(months) | ST10 | Placebo | Total |
|---|---|---|---|
| Mean | 24.8 ± 59.16 | 21.51 ± 38.46 | 23.2 ± 48.4 |
| Time since last OFP dose (months)(months) | ST10 | Placebo | Total |
|---|---|---|---|
| Mean | 36.17 ± 40.1 | 33.34 ± 44.04 | 34.76 ± 41.7 |
| Haemoglobin concentration at baseline(g/dL) | ST10 | Placebo | Total |
|---|---|---|---|
| Mean | 11 ± 1.03 | 11.1 ± 0.85 | 11.05 ± 0.93 |
4 further baseline measures are reported on the registry.
No study locations are listed for this record.
Plan to share: No
The record gives a start of Aug 2011, a primary completion of Oct 2013 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 4 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric maltol
Shield Therapeutics